Browse SPTB

Summary
SymbolSPTB
Namespectrin, beta, erythrocytic
Aliases spherocytosis, clinical type I; EL3; HS2; HSPTB1; Sp beta; beta-I spectrin; membrane cytoskeletal protein; s ......
Chromosomal Location14q24.1-q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, cytoskeleton. Cytoplasm, cell cortex.
Domain PF00307 Calponin homology (CH) domain
PF00435 Spectrin repeat
Function

Spectrin is the major constituent of the cytoskeletal network underlying the erythrocyte plasma membrane. It associates with band 4.1 and actin to form the cytoskeletal superstructure of the erythrocyte plasma membrane.

> Gene Ontology
 
Biological Process GO:0006888 ER to Golgi vesicle-mediated transport
GO:0007015 actin filament organization
GO:0007409 axonogenesis
GO:0007411 axon guidance
GO:0008064 regulation of actin polymerization or depolymerization
GO:0008154 actin polymerization or depolymerization
GO:0010639 negative regulation of organelle organization
GO:0030041 actin filament polymerization
GO:0030042 actin filament depolymerization
GO:0030832 regulation of actin filament length
GO:0030833 regulation of actin filament polymerization
GO:0030834 regulation of actin filament depolymerization
GO:0030835 negative regulation of actin filament depolymerization
GO:0030837 negative regulation of actin filament polymerization
GO:0031333 negative regulation of protein complex assembly
GO:0032271 regulation of protein polymerization
GO:0032272 negative regulation of protein polymerization
GO:0032535 regulation of cellular component size
GO:0032956 regulation of actin cytoskeleton organization
GO:0032970 regulation of actin filament-based process
GO:0032984 macromolecular complex disassembly
GO:0043241 protein complex disassembly
GO:0043242 negative regulation of protein complex disassembly
GO:0043244 regulation of protein complex disassembly
GO:0043254 regulation of protein complex assembly
GO:0043624 cellular protein complex disassembly
GO:0048193 Golgi vesicle transport
GO:0048667 cell morphogenesis involved in neuron differentiation
GO:0051258 protein polymerization
GO:0051261 protein depolymerization
GO:0051493 regulation of cytoskeleton organization
GO:0051494 negative regulation of cytoskeleton organization
GO:0051693 actin filament capping
GO:0061564 axon development
GO:0090066 regulation of anatomical structure size
GO:0097485 neuron projection guidance
GO:1901879 regulation of protein depolymerization
GO:1901880 negative regulation of protein depolymerization
Molecular Function GO:0003779 actin binding
GO:0005085 guanyl-nucleotide exchange factor activity
GO:0005088 Ras guanyl-nucleotide exchange factor activity
GO:0005200 structural constituent of cytoskeleton
GO:0030506 ankyrin binding
GO:0051015 actin filament binding
Cellular Component GO:0005938 cell cortex
GO:0008091 spectrin
GO:0009898 cytoplasmic side of plasma membrane
GO:0014731 spectrin-associated cytoskeleton
GO:0015629 actin cytoskeleton
GO:0030863 cortical cytoskeleton
GO:0030864 cortical actin cytoskeleton
GO:0031235 intrinsic component of the cytoplasmic side of the plasma membrane
GO:0044448 cell cortex part
GO:0098552 side of membrane
GO:0098562 cytoplasmic side of membrane
GO:0099568 cytoplasmic region
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-170984: ARMS-mediated activation
R-HSA-446203: Asparagine N-linked glycosylation
R-HSA-422475: Axon guidance
R-HSA-6807878: COPI-mediated anterograde transport
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-1266738: Developmental Biology
R-HSA-186763: Downstream signal transduction
R-HSA-199977: ER to Golgi Anterograde Transport
R-HSA-2871796: FCERI mediated MAPK activation
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-170968: Frs2-mediated activation
R-HSA-179812: GRB2 events in EGFR signaling
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-2428924: IGF1R signaling cascade
R-HSA-112399: IRS-mediated signalling
R-HSA-2428928: IRS-related events triggered by IGF1R
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-74751: Insulin receptor signalling cascade
R-HSA-445095: Interaction between L1 and Ankyrins
R-HSA-912526: Interleukin receptor SHC signaling
R-HSA-451927: Interleukin-2 signaling
R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling
R-HSA-373760: L1CAM interactions
R-HSA-5683057: MAPK family signaling cascades
R-HSA-5684996: MAPK1/MAPK3 signaling
R-HSA-199991: Membrane Trafficking
R-HSA-392499: Metabolism of proteins
R-HSA-375165: NCAM signaling for neurite out-growth
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-597592: Post-translational protein modification
R-HSA-169893: Prolonged ERK activation events
R-HSA-5673001: RAF/MAP kinase cascade
R-HSA-8853659: RET signaling
R-HSA-180336: SHC1 events in EGFR signaling
R-HSA-112412: SOS-mediated signalling
R-HSA-162582: Signal Transduction
R-HSA-177929: Signaling by EGFR
R-HSA-372790: Signaling by GPCR
R-HSA-74752: Signaling by Insulin receptor
R-HSA-449147: Signaling by Interleukins
R-HSA-2586552: Signaling by Leptin
R-HSA-186797: Signaling by PDGF
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
R-HSA-194138: Signaling by VEGF
R-HSA-166520: Signalling by NGF
R-HSA-187687: Signalling to ERKs
R-HSA-167044: Signalling to RAS
R-HSA-187706: Signalling to p38 via RIT and RIN
R-HSA-948021: Transport to the Golgi and subsequent modification
R-HSA-4420097: VEGFA-VEGFR2 Pathway
R-HSA-5218921: VEGFR2 mediated cell proliferation
R-HSA-5653656: Vesicle-mediated transport
Summary
SymbolSPTB
Namespectrin, beta, erythrocytic
Aliases spherocytosis, clinical type I; EL3; HS2; HSPTB1; Sp beta; beta-I spectrin; membrane cytoskeletal protein; s ......
Chromosomal Location14q24.1-q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SPTB and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolSPTB
Namespectrin, beta, erythrocytic
Aliases spherocytosis, clinical type I; EL3; HS2; HSPTB1; Sp beta; beta-I spectrin; membrane cytoskeletal protein; s ......
Chromosomal Location14q24.1-q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SPTB in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSPTB
Namespectrin, beta, erythrocytic
Aliases spherocytosis, clinical type I; EL3; HS2; HSPTB1; Sp beta; beta-I spectrin; membrane cytoskeletal protein; s ......
Chromosomal Location14q24.1-q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SPTB in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1790.57
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.410.442
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0140.976
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.7040.0425
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.8430.686
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5290.843
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1540.675
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.6130.443
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.9490.242
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.3340.561
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.2150.778
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1450.375
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SPTB in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.89.65.20.482
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.811.92.90.735
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.523.5-140.378
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86016.7-16.70.429
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.427.3-11.90.63
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91633.36.227.10.116
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47750750.0242
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.97.40.51
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.57.7-3.21
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161412.57.15.41
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSPTB
Namespectrin, beta, erythrocytic
Aliases spherocytosis, clinical type I; EL3; HS2; HSPTB1; Sp beta; beta-I spectrin; membrane cytoskeletal protein; s ......
Chromosomal Location14q24.1-q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SPTB. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSPTB
Namespectrin, beta, erythrocytic
Aliases spherocytosis, clinical type I; EL3; HS2; HSPTB1; Sp beta; beta-I spectrin; membrane cytoskeletal protein; s ......
Chromosomal Location14q24.1-q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SPTB. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SPTB.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSPTB
Namespectrin, beta, erythrocytic
Aliases spherocytosis, clinical type I; EL3; HS2; HSPTB1; Sp beta; beta-I spectrin; membrane cytoskeletal protein; s ......
Chromosomal Location14q24.1-q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SPTB. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSPTB
Namespectrin, beta, erythrocytic
Aliases spherocytosis, clinical type I; EL3; HS2; HSPTB1; Sp beta; beta-I spectrin; membrane cytoskeletal protein; s ......
Chromosomal Location14q24.1-q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SPTB expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSPTB
Namespectrin, beta, erythrocytic
Aliases spherocytosis, clinical type I; EL3; HS2; HSPTB1; Sp beta; beta-I spectrin; membrane cytoskeletal protein; s ......
Chromosomal Location14q24.1-q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SPTB and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSPTB
Namespectrin, beta, erythrocytic
Aliases spherocytosis, clinical type I; EL3; HS2; HSPTB1; Sp beta; beta-I spectrin; membrane cytoskeletal protein; s ......
Chromosomal Location14q24.1-q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SPTB collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.